- Home
- AIRT vs ATRA Comparison
AIRT vs ATRA Comparison
Compare AIRT & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRT | ATRA |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 94.2M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AIRT | ATRA |
|---|---|---|
| Price | $30.59 | $9.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | ★ 50.3K | 33.1K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1393.72 | 122.52 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $286,834,000.00 | $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,334.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.98 | N/A |
| 52 Week Low | $18.35 | $3.92 |
| 52 Week High | $35.00 | $19.15 |
Technical Indicators
Market Signals| Indicator | AIRT | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 53.21 |
| Support Level | $27.32 | $8.96 |
| Resistance Level | $34.30 | $11.22 |
| Average True Range (ATR) | 1.87 | 0.61 |
| MACD | 0.15 | 0.06 |
| Stochastic Oscillator | 64.17 | 75.12 |
Price Performance
Historical ComparisonAbout AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include overnight air cargo, ground support equipment, commercial aircraft, engines and parts, digital solutions, and regional airline. The company generates maximum revenue from the overnight air cargo segment.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.